Skip to main content
Quest Diagnostics

Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic

Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic

Authors: Kaufman HW, Bull-Otterson L, Meyer III WA, Huang X, Doshani M, Thompson WW, Osinubi A, Khan MA, Harris A, Gupta N, Van Handel M, Wester C, Mermin J, Nelson N

Citation: Am J Prev Med. 2021 May10; https://doi.org/10.1016/j.amepre.2021.03.011 Online ahead of print

Specialties: Infectious disease, COVID-19, Internal medicine

Download key summary

Related content

Publication
Assessing vulnerability to COVID 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Publication
Hepatitis C virus clearance cascade — United States, 2013–2022
Publication
Hepatitis C Virus Testing During Pregnancy Following Universal Screening Recommendations
On-Demand Webinar
Hepatitis C: Implementing the New Guidelines During the Pandemic

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.